0000000000209992

AUTHOR

Andrea Zini

0000-0003-1486-4507

showing 12 related works from this author

Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19: The Global COVID-19 Stroke Registry.

2023

Background and ObjectivesCOVID-19–related inflammation, endothelial dysfunction, and coagulopathy may increase the bleeding risk and lower the efficacy of revascularization treatments in patients with acute ischemic stroke (AIS). We aimed to evaluate the safety and outcomes of revascularization treatments in patients with AIS and COVID-19.MethodsThis was a retrospective multicenter cohort study of consecutive patients with AIS receiving intravenous thrombolysis (IVT) and/or endovascular treatment (EVT) between March 2020 and June 2021 tested for severe acute respiratory syndrome coronavirus 2 infection. With a doubly robust model combining propensity score weighting and multivariate regress…

Fibrinolytic Agents/therapeutic useCerebral Hemorrhage/complicationsStroke/epidemiologyBrain Ischemia/complicationsTreatment OutcomeIschemic Stroke/epidemiologyCOVID-19/complicationsHumansCohort studiesEndovascular Procedures/adverse effectsRegistriesNeurology (clinical)610 Medicine & healthIntracranial Hemorrhages/etiologyThrombolytic Therapy/adverse effectsResearch Article
researchProduct

Association of prestroke metformin use, stroke severity, and thrombolysis outcome

2020

ObjectiveTo evaluate whether pretreatment with metformin (MET) is associated with less stroke severity and better outcome after IV thrombolysis (IVT), we analyzed a cohort of 1,919 patients with stroke with type 2 diabetes mellitus in a multicenter exploratory analysis.MethodsData from patients with diabetes and ischemic stroke treated with IVT were collected within the European Thrombolysis in Ischemic Stroke Patients (TRISP) collaboration. We applied propensity score matching (PSM) to obtain balanced baseline characteristics of patients treated with and without MET.ResultsOf 1,919 patients with stroke with type 2 diabetes who underwent IVT, 757 (39%) had received MET before stroke (MET+),…

Malemedicine.medical_specialtymedicine.medical_treatment610 Medicine & health030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineFibrinolytic AgentsModified Rankin ScaleInternal medicineDiabetes mellitusEpidemiologymedicineHumansHypoglycemic AgentsThrombolytic Therapycardiovascular diseases10064 Neuroscience Center ZurichStrokeAgedRetrospective Studiesbusiness.industryRecovery of Function10060 Epidemiology Biostatistics and Prevention Institute (EBPI)ThrombolysisMiddle Agedmedicine.diseaseMetformin10040 Clinic for Neurology3. Good healthMetforminStroke2728 Neurology (clinical)Diabetes Mellitus Type 2Propensity score matchingCohortFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugNeurology
researchProduct

Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy.

2021

Summary Background Among asymptomatic patients with severe carotid artery stenosis but no recent stroke or transient cerebral ischaemia, either carotid artery stenting (CAS) or carotid endarterectomy (CEA) can restore patency and reduce long-term stroke risks. However, from recent national registry data, each option causes about 1% procedural risk of disabling stroke or death. Comparison of their long-term protective effects requires large-scale randomised evidence. Methods ACST-2 is an international multicentre randomised trial of CAS versus CEA among asymptomatic patients with severe stenosis thought to require intervention, interpreted with all other relevant trials. Patients were eligib…

Malemedicine.medical_specialtyTime FactorsTime Factormedicine.medical_treatmentCarotid StenosiMEDLINECarotid endarterectomyRate ratioRisk AssessmentAsymptomaticlaw.inventionRandomized controlled triallawRisk Factorscarotid artery stenting (CAS); carotid endarterectomy (CEA)StentmedicineHumansCarotid StenosisStrokeEndarterectomyAgedEndarterectomy Carotidbusiness.industrycarotid arteryRisk FactorArticlesGeneral Medicinetrialmedicine.diseaseSettore MED/22 - CHIRURGIA VASCOLARESurgeryStrokeStenosisTreatment Outcomecarotid artery stenting (CAS)Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREFemaleStentsHuman medicinemedicine.symptomcarotid endarterectomy (CEA)businessHumanLancet (London, England)
researchProduct

Reduced Admissions for Cerebrovascular Events during COVID-19 Outbreak in Italy

2020

Supplemental Digital Content is available in the text.

disease outbreakMalemedicine.medical_treatment030204 cardiovascular system & hematologyItaly; cerebral hemorrhage; disease outbreaks; incidence; ischemic attack transient0302 clinical medicineEpidemiology80 and overMedicineischemic attack transientThrombolytic Therapy10178Acute ischemic stroke10177ThrombectomyAged 80 and overIschemic AttackTransientIncidence (epidemiology)Endovascular ProceduresMiddle AgedHospitalization1006210183ItalyComputingMethodologies_DOCUMENTANDTEXTPROCESSINGSettore MED/26 - NeurologiaFemaleCardiology and Cardiovascular Medicinecerebral hemorrhage; disease outbreaks; incidence; ischemic attack transient; Italy; Aged; Aged 80 and over; COVID-19; Cerebral Hemorrhage; Endovascular Procedures; Female; Hospitalization; Humans; Ischemic Attack Transient; Ischemic Stroke; Italy; Male; Middle Aged; Thrombectomy; Thrombolytic Therapymedicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)RevascularizationSettore MED/261015203 medical and health sciencesHumansAgedIschemic StrokeAdvanced and Specialized Nursingcerebral hemorrhagebusiness.industryOutbreakCOVID-19Emergency medicinedisease outbreaksincidenceBrief ReportsNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

The Gut Microbial Metabolite Trimethylamine-N-Oxide Is Present in Human Cerebrospinal Fluid

2017

Trimethylamine-N-oxide (TMAO) is a small organic molecule, derived from the intestinal and hepatic metabolism of dietary choline and carnitine. Although the involvement of TMAO in the framework of many chronic diseases has been recently described, no evidence on its putative role in the central nervous system has been provided. The aim of this study was to evaluate whether TMAO is present at detectable levels in human cerebrospinal fluid (CSF). CSF was collected for diagnostic purposes from 58 subjects by lumbar puncture and TMAO was quantified by using liquid chromatography coupled with multiple-reaction monitoring mass spectrometry. The molecule was detected in all samples, at concentrati…

0301 basic medicineMalemedicine.medical_specialtyMetaboliteCentral nervous systemTrimethylamine N-oxidelcsh:TX341-641Gut floraSpinal Puncturetrimethylamine-N-oxideMass Spectrometry03 medical and health scienceschemistry.chemical_compoundMethylamines0302 clinical medicineCerebrospinal fluidAlzheimer DiseasePredictive Value of TestsInternal medicinemedicineCholineHumansCarnitineAgedAged 80 and overNutrition and DieteticsbiologyBacteriagut microbiotaCommunicationMiddle Agedbiology.organism_classificationcentral nervous systemGastrointestinal MicrobiomeIntestines030104 developmental biologyEndocrinologymedicine.anatomical_structurechemistryBiochemistryDementiaFemalelcsh:Nutrition. Foods and food supply030217 neurology & neurosurgeryDrug metabolismFood Sciencemedicine.drugChromatography LiquidNutrients
researchProduct

Intravenous thrombolysis for suspected ischemic stroke with seizure at onset

2019

Objective Seizure at onset (SaO) has been considered a relative contraindication for intravenous thrombolysis (IVT) in patients with acute ischemic stroke, although this appraisal is not evidence based. Here, we investigated the prognostic significance of SaO in patients treated with IVT for suspected ischemic stroke. Methods In this multicenter, IVT-registry-based study we assessed the association between SaO and symptomatic intracranial hemorrhage (sICH, European Cooperative Acute Stroke Study II definition), 3-month mortality, and 3-month functional outcome on the modified Rankin Scale (mRS) using unadjusted and adjusted logistic regression, coarsened exact matching, and inverse probabil…

0301 basic medicineMalemedicine.medical_specialtymedicine.medical_treatmentLogistic regressionGUIDELINESCLASSIFICATION3124 Neurology and psychiatryBrain IschemiaEARLY MANAGEMENT03 medical and health sciences0302 clinical medicineALTEPLASEModified Rankin ScaleSeizuresMIMICSInternal medicineMedicineHumansThrombolytic TherapyPLASMINOGEN-ACTIVATOR610 Medicine & healthStrokeContraindicationPOPULATIONAgedAged 80 and overHEALTH-CARE PROFESSIONALSbusiness.industryConfounding3112 NeurosciencesOdds ratioThrombolysisASSOCIATIONMiddle Agedmedicine.diseasePrognosisConfidence intervalStroke030104 developmental biologyTreatment OutcomeNeurologySAFETYFemaleNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Recanalization Therapies in Acute Ischemic Stroke Patients Impact of Prior Treatment With Novel Oral Anticoagulants on Bleeding Complications and Out…

2015

Background— We explored the safety of intravenous thrombolysis (IVT) or intra-arterial treatment (IAT) in patients with ischemic stroke on non-vitamin K antagonist oral anticoagulants (NOACs, last intake <48 hours) in comparison with patients (1) taking vitamin K antagonists (VKAs) or (2) without previous anticoagulation (no-OAC). Methods and Results— This is a multicenter cohort pilot study. Primary outcome measures were (1) occurrence of intracranial hemorrhage (ICH) in 3 categories: any ICH (ICH any ), symptomatic ICH according to the criteria of the European Cooperative Acute Stroke Study II (ECASS-II) (sICH ECASS-II ) and the National Institute of Neurological Disorders and Stroke …

MaleBrain Ischemia/blood/drug therapyVitamin Kmedicine.medical_treatmentendovascular proceduresAnticoagulants/administration & dosage/adverse effects/classification/therapeutic useAdministration OralPilot ProjectsTissue plasminogen activatorBrain IschemiaCohort Studies2737 Physiology (medical)Atrial Fibrillation80 and overThrombolytic TherapyVitamin K/antagonists & inhibitorsStrokethrombolytic therapyAged 80 and overIncidenceAtrial fibrillationThrombolysisMiddle Aged3. Good healthvitamin K antagonistsTreatment OutcomeAdministrationAcute DiseaseCohortCerebral Hemorrhage/chemically induced/epidemiologyFemaleCardiology and Cardiovascular MedicineAtrial Fibrillation/complicationsmedicine.drugOralmedicine.medical_specialtyanticoagulantsnon-vitamin K antagonist oral anticoagulantsFactor Xa Inhibitors/administration & dosage/adverse effects/therapeutic useintracranial hemorrhagesintra-arterial treatment610 Medicine & healthAntithrombins2705 Cardiology and Cardiovascular MedicineDabigatranFibrinolytic AgentsPhysiology (medical)Internal medicinemedicineischemic strokeHumansAgedCerebral HemorrhageIntracerebral hemorrhageFibrinolytic Agents/therapeutic usebusiness.industryAntithrombins/administration & dosage/adverse effects/therapeutic usemedicine.diseaseddc:616.810040 Clinic for Neurologyanticoagulants; endovascular procedures; intra-arterial treatment; intracranial hemorrhages; ischemic stroke; non-vitamin K antagonist oral anticoagulants; thrombolytic therapy; vitamin K antagonistsPropensity score matchingbusinessFactor Xa InhibitorsCirculation
researchProduct

Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention

2021

Background and Purpose: Clinical trials on stroke prevention in patients with atrial fibrillation have consistently shown clinical benefit from either warfarin or non–vitamin K antagonist oral anticoagulants (NOACs). NOAC-treated patients have consistently reported to be at lower risk for intracerebral hemorrhage (ICH) than warfarin-treated patients. The aims of this prospective, multicenter, multinational, unmatched, case-control study were (1) to investigate for risk factors that could predict ICH occurring in patients with atrial fibrillation during NOAC treatment and (2) to evaluate the role of CHA 2 DS 2 -VASc and HAS-BLED scores in the same setting. Methods: Cases were consecutive pa…

MaleAdministration Oral030204 cardiovascular system & hematologySettore MED/110302 clinical medicine80 and overrisk factorsMedicineatrial fibrillationProspective StudiesAged 80 and overatrial fibrillation; cerebral hemorrhage; logistic models; risk factors; white matter; Administration Oral; Aged; Aged 80 and over; Antithrombins; Atrial Fibrillation; Case-Control Studies; Cerebral Hemorrhage; Female; Humans; Male; Middle Aged; Prospective Studies; Risk Factors; StrokeAtrial fibrillationMiddle AgedVitamin K antagonist3. Good healthStrokeAdministrationSettore MED/26 - NeurologiaFemaleCardiology and Cardiovascular Medicinewhite mattermedicine.drugOralmedicine.medical_specialtymedicine.drug_classSettore MED/26Lower riskAntithrombins03 medical and health sciencesInternal medicineHumanscardiovascular diseaseslogistic modelAgedAdvanced and Specialized NursingIntracerebral hemorrhagecerebral hemorrhagebusiness.industryWarfarinmedicine.diseaseClinical trialatrial fibrillation; cerebral hemorrhage; logistic models; risk factors; white matterCase-Control StudiesConcomitantHeart failureNeurology (clinical)businesslogistic models030217 neurology & neurosurgeryStroke
researchProduct

Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality

2022

[Background and Purpose] Recent studies suggested an increased incidence of cerebral venous thrombosis (CVT) during the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the volume of CVT hospitalization and in-hospital mortality during the 1st year of the COVID-19 pandemic compared to the preceding year.

StrokeVaccine-induced immune thrombotic thrombocytopeniaSDG 3 - Good Health and Well-beingCerebral venous thrombosisSARS-CoV-23112 NeurosciencesCOVID-19COVID-19; Cerebral venous thrombosis; Vaccine-induced immune thrombotic thrombocytopenia; Mortality; SARS-CoV-2; StrokeNeurology (clinical)MortalityCardiology and Cardiovascular Medicine3124 Neurology and psychiatryCOVID-19; Cerebral venous thrombosis; Mortality; SARS-CoV-2; Stroke; Vaccine-induced immune thrombotic thrombocytopeniaJournal of Stroke
researchProduct

Intravenous Thrombolysis in Patients Dependent on the Daily Help of Others Before Stroke

2016

Background and Purpose— We compared outcome and complications in patients with stroke treated with intravenous thrombolysis (IVT) who could not live alone without help of another person before stroke (dependent patients) versus independent ones. Methods— In a multicenter IVT-register–based cohort study, we compared previously dependent (prestroke modified Rankin Scale score, 3–5) versus independent (prestroke modified Rankin Scale score, 0–2) patients. Outcome measures were poor 3-month outcome (not reaching at least prestroke modified Rankin Scale [dependent patients]; modified Rankin Scale score of 3–6 [independent patients]), death, and symptomatic intracranial hemorrhage. Unadjusted an…

Malemedicine.medical_treatment030204 cardiovascular system & hematologylaw.inventionCohort Studies0302 clinical medicineRandomized controlled triallawModified Rankin ScaleActivities of Daily Living80 and overThrombolytic TherapyRegistriesStrokeriskAged 80 and overpreexisting disabilityMedicine (all)survivorsThrombolysisMiddle Aged3. Good healthStrokeTreatment OutcomeInfusions intravenous; Intracranial hemorrhages; Outcome assessment (health care); Stroke; Survivors; Administration Intravenous; Aged; Aged 80 and over; Cohort Studies; Female; Humans; Logistic Models; Male; Middle Aged; Stroke; Treatment Outcome; Activities of Daily Living; Independent Living; Registries; Thrombolytic Therapy; Medicine (all); Neurology (clinical); Cardiology and Cardiovascular Medicine; Advanced and Specialized Nursingcontrolled-trialAdministration[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Administration IntravenousFemaleIndependent Livingacute ischemic-strokehemorrhageCardiology and Cardiovascular MedicineCohort studymedicine.medical_specialtyintracranial hemorrhagesstatinsscale03 medical and health sciencesInternal medicinemedicineHumansDementiaAgedoutcome assessment (health care)Advanced and Specialized Nursingreliabilitybusiness.industryOdds ratiomedicine.diseaseConfidence intervalinfusionsSurgeryLogistic Models[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]intravenousiv thrombolysisNeurology (clinical)business030217 neurology & neurosurgeryStroke
researchProduct

Non-office-hours admission affects intravenous thrombolysis treatment times and clinical outcome

2018

In patients treated with intravenous thrombolysis (IVT), an unfavourable ‘non-office-hours effect’ on door-to-needle time (DNT) and clinical outcome has been suggested. This effect has been attributed to a number of factors, mostly related to either less efficient logistics or less (experienced) staffing during non-office hours (NH). These factors could result in longer DNTs and more protocol violations and thus in worse clinical outcome. On the other hand, one could also argue that the workload during NH is lower, which could result in less time delays in the various diagnostic processes and thus in better clinical outcome. Our hypothesis is that admission during NH has a negative effect o…

MaleTime delaysmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentOutcome (game theory)Time-to-TreatmentCohort Studies03 medical and health sciences0302 clinical medicinePatient AdmissionModified Rankin ScaleIschaemic strokemedicineHumansThrombolytic Therapy030212 general & internal medicineStrokeAgedAged 80 and overbusiness.industryThrombolysisMiddle Agedmedicine.diseasestroke3. Good healthMechanical thrombectomyPsychiatry and Mental healthTreatment OutcomeEmergency medicineCohortPhysical therapySurgeryFemaleNeurology (clinical)business030217 neurology & neurosurgeryJournal of neurology, neurosurgery, and psychiatry
researchProduct

Cohort profile: Thrombolysis in Ischemic Stroke Patients (TRISP): a multicentre research collaboration

2018

PurposeThe ThRombolysis in Ischemic Stroke Patients (TRISP) collaboration aims to address clinically relevant questions about safety and outcomes of intravenous thrombolysis (IVT) and endovascular thrombectomy. The findings can provide observational information on treatment of patients derived from everyday clinical practice.ParticipantsTRISP is an open, investigator-driven collaborative research initiative of European stroke centres with expertise in treatment with revascularisation therapies and maintenance of hospital-based registries. All participating centres made a commitment to prospectively collect data on consecutive patients with stroke treated with IVT using standardised definiti…

medicine.medical_treatment2700 General Medicineregistry030204 cardiovascular system & hematologyRECOMMENDATIONS3124 Neurology and psychiatryBrain Ischemia0302 clinical medicineMedicineProspective StudiesRegistries10064 Neuroscience Center ZurichProspective cohort studyIntersectoral CollaborationThrombectomyRISKEndovascular ProceduresThrombolysisGeneral Medicine3. Good healthStrokeCohortrevascularizationAdministration IntravenousINTRAVENOUS THROMBOLYSISthrombolysismedicine.medical_specialtyMEDLINE610 Medicine & healthRevascularizationfunctional outcome; registry; revascularization; stroke; thrombectomy; thrombolysisCLASSIFICATIONfunctional outcomePOOLED ANALYSIS03 medical and health sciencesALTEPLASEFibrinolytic AgentsHumansMETAANALYSISbusiness.industryStatin treatment10040 Clinic for NeurologyIV THROMBOLYSISSYMPTOMATIC INTRACEREBRAL HEMORRHAGE3121 General medicine internal medicine and other clinical medicineIschemic strokeEmergency medicine570 Life sciences; biologyObservational studybusiness030217 neurology & neurosurgeryBMJ open
researchProduct